血液透析患者阿哌沙班稳态药代动力学
七例血液透析患者接受阿哌沙班2.5 mg每日两次共8天,第1天与第8天之间药物显著蓄积,AUC0-24从628增至2054 ng h/ml(P<0.001),谷浓度从45增至132 ng/ml(P<0.001)。透析仅清除4%的药物。五例患者洗脱后接受5 mg每日两次共8天,AUC进一步增至6045 ng h ml(P=0.03),谷浓度增至218 ng/ml(P=0.03),超过肾功能正常患者5 mg剂量的第90百分位。
要点
- 血液透析患者阿哌沙班2.5 mg每日两次的暴露量与肾功能正常患者标准剂量5 mg每日两次相当。
- 阿哌沙班5 mg每日两次在血液透析患者中导致超治疗水平,应避免使用。
- 透析仅清除4%的阿哌沙班。
核心结论
- 血液透析患者阿哌沙班2.5 mg每日两次的药物暴露量与肾功能正常患者标准剂量5 mg每日两次相当,可能作为华法林预防透析患者卒中的合理替代。
- 阿哌沙班5 mg每日两次在血液透析患者中导致超治疗水平,应避免使用。
研究设计与样本
- 七例血液透析患者接受阿哌沙班2.5 mg每日两次共8天,第1天和第8天(非透析日)给药前后采集血样。
- 第9天给予2.5 mg后透析期间每小时监测阿哌沙班水平。
- 经过5天洗脱期后,五例患者接受阿哌沙班5 mg每日两次共8天。
主要发现
- 2.5 mg剂量第1天至第8天观察到药物显著蓄积,AUC0-24从628增至2054 ng h/ml(P<0.001),谷浓度从45增至132 ng/ml(P<0.001)。
- 第9天给予2.5 mg后透析期间仅清除4%的药物。
- 5 mg剂量AUC进一步增至6045 ng h/ml(P=0.03),谷浓度增至218 ng/ml(P=0.03),超过肾功能正常患者5 mg剂量的第90百分位。
临床怎么用
- 作者认为血液透析患者阿哌沙班2.5 mg每日两次可能作为华法林预防卒中的合理替代。
- 作者认为阿哌沙班5 mg每日两次在血液透析患者中应避免使用。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
It is unclear whether warfarin is protective or harmful in patients with ESRD and atrial fibrillation. This state of equipoise raises the question of whether alternative anticoagulants may have a therapeutic role. We aimed to determine apixaban pharmacokinetics at steady state in patients on hemodialysis. Seven patients received apixaban 2.5 mg twice daily for 8 days. Blood samples were collected before and after apixaban administration on days 1 and 8 (nondialysis days). Significant accumulation of the drug was observed between days 1 and 8 with the 2.5-mg dose. The area under the concentration-time curve from 0 to 24 hours increased from 628 to 2054 ng h/ml (P<0.001). Trough levels increased from 45 to 132 ng/ml (P<0.001). On day 9, after a 2.5-mg dose, apixaban levels were monitored hourly during dialysis. Only 4% of the drug was removed. After a 5-day washout period, five patients received 5 mg apixaban twice daily for 8 days. The area under the concentration-time curve further increased to 6045 ng h/ml (P=0.03), and trough levels increased to 218 ng/ml (P=0.03), above the 90th percentile for the 5-mg dose in patients with preserved renal function. Apixaban 2.5 mg twice daily in patients on hemodialysis resulted in drug exposure comparable with that of the standard dose (5 mg twice daily) in patients with preserved renal function and might be a reasonable alternative to warfarin for stroke prevention in patients on dialysis. Apixaban 5 mg twice daily led to supratherapeutic levels in patients on hemodialysis and should be avoided.
引用
- Mavrakanas TA, Samer CF, Nessim SJ, et al. Apixaban Pharmacokinetics at Steady State in Hemodialysis Patients. J Am Soc Nephrol. 2017. PMID: 28302754. doi:10.1681/ASN.2016090980
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。